Greater First Year Effectiveness Drives Favorable Cost-Effectiveness of Brand Risedronate Versus Generic or Brand Alendronate: Modeled Canadian Analysis
Osteoporosis International - United Kingdom
doi 10.1007/s00198-007-0504-z
Full Text
Open PDFAbstract
Available in full text
Date
November 16, 2007
Authors
Publisher
Springer Science and Business Media LLC